Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history

» Details

Guru Trades

Q4 2015

IBB Guru Trades in Q4 2015

Louis Moore Bacon 36,421 sh (New)
Steven Cohen 5,000 sh (New)
» More
Q1 2016

IBB Guru Trades in Q1 2016

George Soros 67,600 sh (New)
Steven Cohen Sold Out
Louis Moore Bacon Sold Out
» More
Q2 2016

IBB Guru Trades in Q2 2016

John Burbank 520,000 sh (unchged)
George Soros Sold Out
» More
Q3 2016

IBB Guru Trades in Q3 2016

George Soros 777 sh (New)
Stanley Druckenmiller 67,800 sh (New)
Ken Fisher 1,417 sh (New)
» More

Ratios

vs
industry
vs
history
P/E(ttm) 18.12
IBB's P/E(ttm) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IBB: 18.12 )
Ranked among companies with meaningful P/E(ttm) only.
IBB' s P/E(ttm) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 23.14
Current: 18.12
0
23.14
PE(NRI) 18.12
IBB's PE(NRI) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IBB: 18.12 )
Ranked among companies with meaningful PE(NRI) only.
IBB' s PE(NRI) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 23.14
Current: 18.12
0
23.14
P/B 4.28
IBB's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IBB: 4.28 )
Ranked among companies with meaningful P/B only.
IBB' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 5.58
Current: 4.28
0
5.58

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.17
IBB's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IBB: 0.17 )
Ranked among companies with meaningful Dividend Yield only.
IBB' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.17
Current: 0.17
0
0.17
Yield on cost (5-Year) 0.17
IBB's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IBB: 0.17 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
IBB' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.17
Current: 0.17
0
0.17

More Statistics

Short Percentage of Float0.00%
52-Week Range $241.49 - 343.11
Shares Outstanding (Mil)28,900,000.00
» More Articles for IBB

Headlines

Articles On GuruFocus.com
US Market Indexes Continue to Reach New Highs Dec 08 2016 
Southern Company: Dividend Achiever Nearing a 5% Yield Dec 08 2016 
Royce Funds: What's the Outlook for U.S. Small-Caps? Dec 08 2016 
Big Insider Sell at Apple, Buy at Acushnet Dec 08 2016 
Mason Hawkins Adds to FedEx Dec 08 2016 
Altria Group Announces Quarterly Dividend Dec 08 2016 
Jim Chanos Adds to Starz Dec 08 2016 
Lam Research Increases Dividend by a Solid 50% Dec 08 2016 
Avoid Advanced Micro Devices Dec 08 2016 
Lululemon Is a Buy Dec 08 2016 

More From Other Websites
Small-Cap ETFs Poised For Big Weekly Gains And Biotechs Bounce Back Dec 09 2016
Trump's pledge to rein in drug prices takes bite out of Seattle-area biotech stocks Dec 08 2016
The top widely held ETFs Dec 08 2016
3 Reasons To Shrug Off Trump's Rhetoric On Drug Prices Dec 08 2016
S&P 500 ETFs Set New Highs, But Biotechs Give Back Most Of Trump Rally Dec 07 2016
Ovid Therapeutics CEO: US biotech best in the world Dec 07 2016
Trump Targets Drug Prices And Apple, Seeks '5 Minutes' With Offshoring Firms Dec 07 2016
Biotech Only Sector in the Red as Trump Vows to Crackdown on Drug Pricing, Biggest Movers Dec 07 2016
Drug Stocks Topple On Donald Trump's Pledge To Bring Down Drug Prices Dec 07 2016
President-elect Trump’s promise to bring down drug prices sends biotech and pharma ETFs slumping Dec 07 2016
Trump Vows to Slash Drug Prices, Sends Biotech Stocks Lower Dec 07 2016
Sonnenfeld: Trump is not a theorist, he's a pragmatist Dec 07 2016
Drug pressure deja vu? Dec 07 2016
This indicator says the stock market’s celebration has gone too far Dec 07 2016
Biotech ETFs: So Much For The Trump Bounce Dec 07 2016
Bernie Sanders' 'Trump Proposal' To Lower Drug Prices Blocked By Senate Republicans Dec 07 2016
Trump's Drug Pricing Comment Sends Biotech Stocks Into Free-Fall Dec 07 2016
President-elect Trump's biotech comments sharply lower biotech ETFs Dec 07 2016
Stock Market Analysis for Week Ending 12/2/16 Dec 02 2016
Look at Silver Miners and Some Names That Have Pulled Back Dec 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK